Communiqués Design Therapeutics, Inc.

Actions

DSGN

US25056L1035

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 28/09/2026			Varia. 5j.	Varia. 1 janv.
12,36 ^USD	+1,98%		+0,98%	+31,77%

03/08	Design Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
03/08	Design Therapeutics : réduction de la perte nette au deuxième trimestre	MT

Communiqués

02/09	Design Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare Conference	GL
03/08	Design Therapeutics : Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results	PU
03/08	Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results	GL
30/06	Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1	GL
28/05	Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference	GL
18/05	Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia	GL
18/05	Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia	AQ
17/05	Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026	GL
28/04	Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates	GL
09/03	Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates	GL
18/02	Design Therapeutics to Participate in Upcoming Investor Conferences	GL
26/11	Design Therapeutics to Participate in Upcoming Investor Conferences	GL
26/11	Design Therapeutics to Participate in Upcoming Investor Conferences	AQ
05/11	Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results	GL
10/09/25	Design Therapeutics Appoints Justin Gover to Board of Directors	GL
10/09/25	Design Therapeutics Appoints Justin Gover to Board of Directors	AQ
27/08/25	Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference	GL
07/08/25	Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results	GL
07/08/25	Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results	AQ
04/06/25	Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2	GL
28/05/25	Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference	GL
28/05/25	Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference	AQ
13/05/25	Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference	GL
07/05/25	Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results	GL
01/05/25	Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy	GL